TDAV Detection via Segmented PCR Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The diagnosis and treatment of Theiler's disease in horses are hindered by the unknown cause of the disease and the delay between exposure to biologics and the onset of acute hepatitis, with existing methods failing to effectively detect and address the underlying viral agent.
Innovation Solution
Identification and characterization of Theiler's disease-associated virus (TDAV), a member of the Flaviviridae family, including its genomic nucleotide and amino acid sequences, along with methods and reagents for detecting TDAV in biological samples, enabling diagnosis, treatment, and prevention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods are used, then the diagnostic process is simple, but the detection precision is insufficient to identify the viral cause of Theiler's disease
Solution Approach 1:
The diagnostic approach is segmented into multiple stages: initial screening using conventional methods, followed by targeted molecular detection (PCR) if suspicious cases are identified. This segmentation allows the system to maintain simplicity for routine cases while achieving high precision for suspected TDAV cases without requiring all cases to undergo complex procedures.
Solution Approach 2:
Molecular detection methods serve as an intermediary between conventional diagnostic methods and definitive diagnosis. The intermediary molecular tests (detecting viral RNA or specific antibodies) bridge the gap by providing high-specificity detection capability that can be selectively applied, thus improving overall detection precision without making the entire diagnostic system complex.
2Reliability
If the cause of Theiler's disease remains unknown, then existing diagnostic methods can be used, but the treatment and prevention effectiveness is reduced
Solution Approach 1:
The patent implements preliminary molecular detection of TDAV (through viral RNA detection or specific antibody detection) before initiating treatment. This preliminary action identifies the true cause of the disease in advance, allowing clinicians to select appropriate treatments and prevention strategies targeted at viral hepatitis rather than idiopathic liver disease, thereby improving treatment reliability.
Solution Approach 2:
The diagnostic system incorporates feedback through molecular detection results that inform subsequent treatment decisions. By detecting TDAV-specific markers and feeding this information back to clinicians, the system enables evidence-based treatment selection and prevention措施 implementation, directly addressing the information loss about disease etiology and improving therapeutic outcomes.
3Measurement precision
If there is a delay between biologic exposure and hepatitis onset, then the temporal relationship is unclear, but the association with biologics may be missed
Solution Approach 1:
The patent recommends performing TDAV molecular detection at the onset of hepatitis symptoms even when the delay since biologic exposure is unknown or prolonged. This preliminary action captures the viral etiology information before it is lost, allowing retrospective identification of the biologic-exposure association regardless of the time delay, thus maintaining detection precision despite temporal uncertainty.
Data Source
AI summary
This disclosure relates to Theiler's disease-associated virus (“TDAV”), reagents relating thereto, and methods for detecting, using, and/or treating diseases associated with TDAV.